Trial Profile
A Randomized, Double-blind, Placebo-controlled Phase II Study of BNC210 in Adults With Post-Traumatic Stress Disorder (PTSD).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs BNC 210 (Primary)
- Indications Post-traumatic stress disorders
- Focus Therapeutic Use
- Acronyms RESTORE
- Sponsors Bionomics
- 10 May 2021 According to a Bionomics media release, the dose of BNC-210 for Phase 2b PTSD trial has been selected based on data from this trial.
- 03 Oct 2018 Status changed from active, no longer recruiting to completed.
- 02 Oct 2018 Top-line results presented in a Bionomics media release.